Señales en vivo de MCUJF | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 12:27):

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States...

Stats
Volumen de hoy	2 800.00
Volumen promedio	1 274.00
Capitalización de mercado	7.72M
EPS	$0 ( 2024-04-04 )
Próxima fecha de ganancias	( $0 ) 2024-05-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.57
ATR14	$0 (0.00%)

Medicure Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medicure Inc. Finanzas

Annual	2023
Ingresos:	$21.69M
Beneficio Bruto:	$13.56M (62.48 %)
EPS:	$-0.0883

FY	2023
Ingresos:	$21.69M
Beneficio Bruto:	$13.56M (62.48 %)
EPS:	$-0.0883

FY	2022
Ingresos:	$23.07M
Beneficio Bruto:	$16.08M (69.69 %)
EPS:	$0.130

FY	2021
Ingresos:	$21.74M
Beneficio Bruto:	$12.71M (58.46 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

Medicure Inc.

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.